demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID 19 hospitalizedCOVID 19 all comersCOVID-19 mild to moderateCOVID-19 severe or critically
Immunosuppressants drugs
adalimumab Fakharian
anakinra SAVE-MORE CORIMUNO-ANA-1
anti-interleukin-6
Levilimab V.Lomakin ...
sarilumab CORIMUNO-SARI-1 ... sarilumab Sanofi phase 3 outside US
sarilumab high dose (400mg) Lescure ...
sarilumab low dose (200mg) Lescure ...
tocilizumab EMPACTA RECOVERY NCT04479358 ... NCT04434717 ... Soin AS ... RCT-TCZ-COVID-19 NCT04412772 ... Declercq J ... NCT04577534 ... Rutgers EU-CTR2020-001375-32 ... Dongsheng Wang EU-CTR2020-001748-24 ... BACC Bay Tocilizumab Trial MARIPOSA CORIMUNO-TOCI-ICU ... CORIMUNO-TOCI-1 ... REMAP-CAP ... Rosas ... Veiga Talaschian COVACTA ...
canakinumab Sheng ... CAN-COVID
janus kinase (JAK) inhibitor
baricitinib COV-BARRIER ACTT-2 ... RECOVERY COV-BARRIER ...
ruxolitinib Cao
TD-0903
TD-0903 10mg Singh ...
TD-0903 1mg Singh ...
TD-0903 3mg Singh ...
tofacitinib STOP-COVID ...
lenzilumab LIVE-AIR ...

9 studies excluded by filtering options 0

5180 TACROVID, 2021 000selection pending
5357 Cavalli, 2020 0130selection pending
5398 Ana-COVID (Huet), 2020 0133selection pending
5523 Toniati, 2020 2990excludednot a RCTrisk of bias not avaialble
5526 Price, 2020 2130excludednot a RCTrisk of bias not avaialble
6020 Annane, 2020 0130selection pending
6359 Kooistra, 2020 0100selection pending
6789 Amra, 2021 113high risk of bias
6879 Kumar, 2021 113high risk of bias